DIABETES EPIDEMIC = DIAGNOS INC. THE SOLUTION Last time I checked the Diabetes epidemic is getting worse year over year..!
The available market for Diabetic Retinopathy scanning is very large, with annual scanning recommended for over 400million diabetics worldwide – existing systems using manual interpretation by specialists cannot cope – CARA automates the process – at the local (doctor office) level, a systemic change.
The company has been active with market penetration strategies for several years, gaining footholds in 16 countries to date and increasing. The question is when do these tests transition to larger scale, ongoing contracts? While it is difficult to determine exactly when, we believe the transition to automatic scanning is inevitable disruptive technology – medical systems are not able to cope with the large and increasing number of diabetics, which need screening every year – and if not done (which it is not), the costs to treat become huge (now ~20% of health care spending). The answer is to automate, bringing routine scanning out of the exclusive realm of a short supply of ophthalmologists and into the local doctor’s office, where immediate action can be taken. We believe governments / health care officials increasingly see the benefits of making this change.
Adoption curve expected to continue to accelerate for proprietary technology applying artificial intelligence in healthcare diabetes market.
As a first mover with industry-leading accuracy, DIAGNOS Inc. has succeeded in developing partnerships with Novartis,Bayer, AND Novo Nordisk, recognized pharma leaders in the diabetes industry. |
CARA technology is the company’s flagship product offering, through which DIAGNOS is using AI in more than 16 countries, to help detect anomalies in the retina due to diabetic retinopathy. DIAGNOS has screened more than 225,000 patients through the CARA system, which combines the latest in advanced retinal imaging with clinical interpretation of the images
DIAGNOS has successfully developed an AI platform ‘FLAIRE’. The platform is a powerful AI engine that provides the capability of analyzing large and complex data sets. It was developed to analyze data quickly at the lowest cost possible in any of the primary facilities. The company is likely to expand its AI technology platform to new pathology discoveries that will benefit diabetic patients.
CARA is an innovative application that uses AI for early detection of lesions in the retina that cause diabetic retinopathy. If not treated, it results in vision loss and, ultimately, blindness. CARA’s key objective is to reduce costs for governments and primary care facilities while enabling detection of eye disease at the GP level.
CARA being a first mover in this disruptive technology, may be having a tuff time cutting through government’s red tape, but they are making inroads in other ways, breaking cultural barriers using local representatives.
It’s only a matter of time before new contracts start rolling in. We are the only company with government approval. I think if we had a little competition it would help Diagnos in the long run.
In addition to CARA, which is in the production phase and remains the key sales contributor, the company has actively been developing other healthcare-focused software tools as well, which are in different phases of development. CARDIO is another important software being tested by DIAGNOS in four countries, after CARA, and appears to have strong growth potential. A few other healthcare-focused software tools, which are presently in the development phase, include OCT, Sleep Apnea and Alzheimer’s disease.
As for the abid report, I will finish off with what it says in the disclosure agreement.
Past performance of securities described directly or indirectly in this report should not be taken as an indication or
guarantee of future results. The price, value of, and income from any of the financial securities described in this report may rise as well as fall and may be affected by simple and complex changes in economic, financial and political factors.
There is a 400 million dollar playing field and Diagnos is the first to step onto it. There has to be a few more Mexican sized contracts to be had. Compounding at least once a year. It’s only a matter of time before the stock price heads north again like a freighter with ten tons of steel. There’s No stopping her!